6-Mercapto-9-(β-d-arabinofuranosyl)purine (ara-6-MP) was found to be a competitive inhibitor of L1210 adenosine deaminase when β-d-arabinosyladenine (ara-A) was used as substrate (pseudoproduct inhibition). The phosphorylation of adenosine, ara-A, and β-d-ribosyl-6-methylthiopurine did not appear to be affected by ara-6-MP. Studies on the kinetic parameters of adenosine deaminase from two L1210 lines, ara-6-MP-sensitive L1210 and ara-6-MP-resistant L1210 (L1210/ara-6-MP), indicated that the L1210/ara-6-MP subline had mutated. Mice bearing L1210 cells survived longer when treated with ara-A plus ara-6-MP than when treated with either agent alone. No such advantage of the combination drug treatment was seen with mice bearing the line resistant to ara-6-MP (L1210/ara-6-MP).
Supported by Grant CA12327 from the National Cancer Institute of the NIH.